METTL3 mediates resistance to other chemotherapeutic drugs, including platinum‐etoposide in Small Cell Lung Cancer (SCLC), doxorubicin, 5‐fluorouracil (5‐FU), and oxaliplatin in CRC, Idarubicin in AML, and docetaxel in breast cancer.114, 118, 119, 120, 121, 122. Here, METTL3 is linked to acute myeloid leukemia.